ObjectiveTo analyze the role of CRUSADE score in assessing the risk of gastrointestinal bleeding in patients with coronary heart disease treated with antiplatelet therapy.

MethodsA total of 145 patients with coronary heart disease treated with antiplatelet drug for more than one year were selected and divided into gastrointestinal bleeding group(n=45) and non-gastrointestinal bleeding group(n=100) according to whether the patients had gastrointestinal bleeding or not.The clinical characteristics were compared, and the risk of gastrointestinal bleeding in two groups was evaluated by CRUSADE score.

ResultsThe age of the patients in gastrointestinal bleeding group was significantly higher than that in non-gastrointestinal bleeding group(P < 0.01).The proportion of peptic ulcer and bleeding history in patients in gastrointestinal bleeding group was significantly higher that in non-gastrointestinal bleeding group(P < 0.01).There was no significant difference in gender, smoking history, Helicobacter pylori infection history, abnormal history of liver and kidney function, oral clopidogrel bisulfate tablet, aspirin enteric-coated tablet and the combination rate of the two drugs in two groups(P>0.05).The result of CRUSADE score showed that the risk degree of patients in gastrointestinal bleeding group was significantly higher than that in non-gastrointestinal bleeding group(P < 0.01).

ConclusionsThe use of CRUSADE score in patients with coronary heart disease treated with antiplatelet therapy is beneficial to assess the risk of gastrointestinal bleeding.For patients with CRUSADE score of high risk and very high risk of gastrointestinal bleeding, proton pump inhibitor can be used to reduce the risk of gastrointestinal bleeding caused by long-term use of antiplatelet drug.